Creative_Antibiotics_Ulf_Boberg
Ulf Boberg, CEO Creative Antibiotics

Creative Antibiotics announces positive animal data with the substance INP-11252 for treatment of pulmonary infection

Creative Antibiotics announces positive animal data with the substance INP-11252 for treatment of pulmonary infection

Creative Antibiotics announces the results of two separate studies of the progression of infection with the gram-negative bacterium Pseudomonas aeruginosa in mice. The studies used a lung model designed to mimic clinically relevant situations. One found a lower incidence of bacteria in the lungs and other organs after treatment with INP-11252 compared with the control group. INP-11252 does not kill the bacterium, but “disarms it” to allow the body’s natural defences to eliminate it. The reduced bacterial load in animals treated with INP-11252 confirms the hypothesis that it is possible to disarm the bacterium by targeting its virulence mechanism, the type III secretion system (T3SS). The other study found significantly improved survival in the animals that were treated with INP-11252.
“This is confirmation that the innovative concept that we had already demonstrated to work in a laboratory environment also works in vivo, in a living animal,” says Ulf Boberg, the company’s CEO. “This is a crucial step in the development of the company and the project, encouraging us to conduct further experiments to confirm these positive results and continue to develop INP-11252 for eventual human testing.”
The natural compound INP-11252 is in-licensed from the Eskitis Institute at Griffith University in Brisbane, Australia. Creative Antibiotics has collaborated with the Eskitis Institute since 2008, searching through Eskitis’ extensive library of natural compounds in the search for suitable substances with efficacy on the T3SS.

For more information, go to
Creative Antibiotcs homepage.